Page last updated: 2024-12-04

chrysanthemic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

chrysanthemic acid: occurs as esters in pyrethrum flowers; RN given refers to cpd without isomeric designation; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

chrysanthemic acid : A monocarboxylic acid that is cyclopropanecarboxylic acid substituted by two methyl groups at position 2 and a 2-methylprop-1-en-1-yl group at position 3. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID2743
CHEMBL ID1437285
CHEBI ID3680
SCHEMBL ID62874
MeSH IDM0049983

Synonyms (91)

Synonym
EN300-24002
2,2-dimethyl-3-(2-methylprop-1-en-1-yl)cyclopropane-1-carboxylic acid
chrysanthemic acid (cis/trans=1:10)
BRD-A52893269-001-02-4
chrysamthemic acid
DIVK1C_006537
KBIO1_001481
SDCCGMLS-0066800.P001
nsc 11779
cyclopropanecarboxylic acid, 2,2-dimethyl-3-(2-methyl-1-propenyl)-
2,2-dimethyl-3-(2-methylpropenyl)cyclopropanecarboxylic acid
d,l-cis,trans-chrysanthemic acid
ccris 2496
cyclopropanecarboxylic acid, 2,2-dimethyl-3-(2-methylpropenyl)-
2,2-dimethyl-3-(2-methyl-1-propenyl)cyclopropanecarboxylic acid
brn 2043418
ai3-20453
einecs 233-941-2
SPECTRUM4_001755
SPECTRUM_001622
chrysanthemumic acid
wln: l3tj a1 a1 bvq c1uy1&1
nsc-11779
nsc11779 ,
3-isobutenyl-2,2-dimethylcyclopropanecarboxylic acid
cyclopropanecarboxylic acid,2-dimethyl-3-(2-methyl-1-propenyl)-
cyclopropanecarboxylic acid,2-dimethyl-3-(2-methylpropenyl)-
2-(1-isobutenyl)-3,3-dimethylcyclopropanecarboxylic acid
chrysanthemummonocarboxylic acid
(.+-.)-chrysanthemumic acid
BSPBIO_003526
chrysanthemic acid
10453-89-1
2,2-dimethyl-3-(2-methylprop-1-en-1-yl)cyclopropanecarboxylic acid
chrysanthemumsaeure
CHEBI:3680 ,
NCGC00094564-01
NCGC00094564-02
KBIO2_007238
KBIO2_002102
KBIOSS_002102
NCI60_000424
KBIO2_004670
KBIO3_002752
KBIOGR_002230
SPECTRUM2_001682
SPECPLUS_000441
SPECTRUM3_001926
SPBIO_001604
SPECTRUM1504800
SPECTRUM5_000610
NCGC00094564-03
AKOS001204877
2,2-dimethyl-3-(2-methylprop-1-enyl)cyclopropane-1-carboxylic acid
FT-0657800
A800997
cyclopropanecarboxylic acid, 2,2-dimethyl-3-(2-methyl-1-propen-1-yl)-
unii-774ih300i2
774ih300i2 ,
2-09-00-00047 (beilstein handbook reference)
dl-cis/trans-chrysanthemic acid
GZ12750000
cyclopropanecarboxylic acid, 2,2-dimethyl-3-(2-methylpropenyl)-, dl-cis/trans-
niosh/gz1275000
CHEMBL1437285
2,2-dimethyl-3-(2-methylprop-1-enyl)cyclopropanecarboxylic acid
CCG-38773
SCHEMBL62874
AKOS016042366
3-(2-methylprop-1-enyl)-2,2-dimethylcyclopropanecarboxylic acid
3- (2-methyl-1-propenyl) -2, 2-dimethylcyclopropanecarboxylic acid
3-(2-methyl-1-propenyl)-2,2-dimethylcyclopropanecarboxylic acid
(.+/-.)-chrysanthemumic acid
W-108810
mfcd00057698
SR-05000002402-1
sr-05000002402
dl-chrysanthemic acid
pyrethrin metabolite
DTXSID30871866
FT-0705410
AS-16143
BRD-A52893269-001-03-2
STL182755
2,2-dimethyl-3-(2-methylprop-1-en-1-yl)cyclopropanecarboxylicacid
2,2-dimethyl-3-(2-methyl-1-propenyl)cyclopropanecarboxylicacid
trans-(+/-)-2,2-dimethyl-3-(2-methylprop-1-enyl)cyclopropanecarboxylic acid
CS-0063329
F74781
HY-114502
Z166667648
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
cyclopropanesCyclopropane and its derivatives formed by substitution.
monocarboxylic acidAn oxoacid containing a single carboxy group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (30)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (16.67)18.7374
1990's2 (6.67)18.2507
2000's8 (26.67)29.6817
2010's12 (40.00)24.3611
2020's3 (10.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 32.59

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index32.59 (24.57)
Research Supply Index3.43 (2.92)
Research Growth Index4.98 (4.65)
Search Engine Demand Index42.09 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (32.59)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (3.33%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other29 (96.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]